Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets

Annals of Surgical Oncology

Volumn 21, Issue 12, 2014, Pages 3827-3834

  Zhu, Andrew X ^a   Borger, Darrell R ^a   Kim, Yuhree ^b   Cosgrove, David ^b   Ejaz, Aslam ^b   Alexandrescu, Sorin ^c   Groeschl, Ryan Thomas ^d   Deshpande, Vikram ^a   Lindberg, James M ^e   Ferrone, Cristina ^a   Sempoux, Christine ^f   Yau, Thomas ^g   Poon, Ronnie ^g   Popescu, Irinel ^c   Bauer, Todd W ^e   Gamblin, T Clark ^d   Gigot, Jean Francois ^f   Anders, Robert A ^b   Pawlik, Timothy M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c FUNDENI CLINICAL INSTITUTE   (Romania)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CTNNB1 PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; MAP2K1 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; DNA EXTRACTION; FEMALE; GENE MUTATION; HEMIHEPATECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER RESECTION; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE N RAS; OVERALL SURVIVAL; PERINEURAL INVASION; BILE DUCT NEOPLASMS; CANCER GRADING; CANCER STAGING; CHOLANGIOCARCINOMA; DNA MICROARRAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; INTRAHEPATIC BILE DUCT; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR RECURRENCE;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84918820210     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3828-x     Document Type: Article

References (34)

1. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–7.
2. Poultsides GA, Zhu AX, Choti MA, et al. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817–37.
3. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
4. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol. 2010;28:3531–40.
5. Sia D, Tovar V, Moeini A, et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32:4861–70.
6. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72–9.
7. Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 2002;197:624–31.
8. Voss JS, Holtegaard LM, Kerr SE, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013;44:1216–22.
9. Xu RF, Sun JP, Zhang SR, et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 2011;65:22–6.
10. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45:1470–3.
11. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013;32:3091–100.
12. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021–31.e15.
13. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146–58.
14. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137–44.
15. Bazan V, Agnese V, Corsale S, et al. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol. 2005;16(Suppl 4):iv50–5.
16. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br J Cancer. 2001;85:692–6.
17. Woo HG, Park ES, Thorgeirsson SS, et al. Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog. 2011;50:235–43.
18. Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. AmJPathol. 2003;163:1371–8.
19. Minguez B, Tovar V, Chiang D, et al. Pathogenesis of hepatocellular carcinoma and molecular therapies. CurrOpinGastroenterol. 2009;25:186–94.
20. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10:77–82.
21. Robertson S, Hyder O, Dodson R, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013;44:2768–73.
22. Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000;47:721–7.
23. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144:829–40.
24. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.
25. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.
26. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–34.
27. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621–5.
28. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552–8.
29. Chan-On W, Nairismagi ML, Ong CK, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45:1474–8.
30. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke–associated cholangiocarcinoma. Nat Genet. 2012;44:690–3.
31. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.
32. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28:266–72.
33. Riener MO, Bawohl M, Clavien PA, et al. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer. 2008;47:363–7.
34. Ross JS, Wang J, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinoma revealed by next-generation sequencing. Oncologist. 2014;19:235–42.